Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
salmeterol xinafoate + triamcinolone acetonide
- Development stage
- Preclinical
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Inhalation
01
Overview
This drug is a fixed-dose combination of two active pharmaceutical ingredients used in the management of asthma and other respiratory diseases: - **Salmeterol xinafoate** is a long-acting beta2-adrenergic receptor agonist (LABA) that acts as a bronchodilator by relaxing airway smooth muscle, leading to improved airflow and symptom control. - **Triamcinolone acetonide** is an inhaled corticosteroid that reduces airway inflammation, thereby decreasing symptoms and exacerbations associated with asthma. The combination leverages the complementary mechanisms of action—bronchodilation from salmeterol and anti-inflammatory effects from triamcinolone—to provide superior asthma control compared to higher doses of inhaled corticosteroids alone. This approach can improve lung function, reduce rescue medication use, decrease nighttime awakenings, and increase symptom-free days in patients with persistent asthma[1][2]. The combination is typically administered via inhalation.
- Other names
- salmeterol xinafoate + triamcinolone acetonide
02
Targets
GR (Glucocorticoid receptor)ADRB2 (β2)
Beyond the preview
Go deeper on salmeterol xinafoate + triamcinolone acetonide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on salmeterol xinafoate + triamcinolone acetonide.